Our Pipeline

Focusing on high unmet medical needs, we synergize compelling science, technology, and collaborative approaches to create a deep pipeline of best-in-class small molecules, CAR-T therapies, and biologics in oncology and immunology.

Oncology

Program
Target
Indication
Modality
Preclinical
Phase 1
Phase 2
Phase 3
Approved
5101
CD19
Relapsed/refractory non-Hodgkin lymphoma (rrNHL)
CAR-T
5201
CD19
Relapsed/refractory chronic lymphocytic leukemia and Richter transformation (rrCLL/RT)
CAR-T
5301
BCMA
Relapsed/refractory multiple myeloma (rrMM)
CAR-T
ADP-A2M4CD8*
MAGE-A4
Head & neck cancer
TCR-T
>5 programs
Multiple
Hematological oncology and solid tumors
CAR-T
>5 programs
Multiple
Solid tumors indications
Small molecule

*Clinical collaboration and exclusive license and option agreement with Adaptimmune, announced on 30 May 2024

Immunology

Program
Target
Indication
Modality
Preclinical
Phase 1
Phase 2
Phase 3
Approved
3667
TYK2
Systemic lupus erythematosus (SLE)
Small molecule
3667
TYK2
Dermatomyositis (DM)
Small molecule
>5 programs
Multiple
Inflammation/auto-immune
Small molecule

Visit our Clinical Trials Portal

Clinical trials are a critical part of our journey to evaluate investigational treatments and gain approval from health authorities such as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

At Galapagos, we organize clinical trials in various therapeutic areas, conducting research that paves the way for innovative solutions.

Visit our Clinical Trials portal to explore the fascinating world of clinical trials. Discover how they’re set up and gain insight into what’s important when considering participation.

Our stories

More about our company, science and people

We curate a series of inspiring stories about how we are #LivingInnovation at Galapagos

Partnerships

Work with us!

We are adding new capabilities, technologies and product candidates through internal and external innovation. Let’s start #PioneeringForPatients, together!

Investor Hub

All information for investors…

… centralized in one Investor Hub. Discover how we aim to create value for all our stakeholders.